Roche to restructure its manufacturing network for small molecules
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) plans to restructure its manufacturing network for small molecules to address current underutilisation as a result of its evolving portfolio. A new generation of specialised medicines based on small molecules requires novel manufacturing technologies and will be produced in lower volumes than traditional medicines.
Global partners announce donation of 500 millionth dose of azithromycin
- Details
- Category: Pfizer
The International Trachoma Initiative (ITI), Pfizer Inc. and International Coalition for Trachoma Control (ICTC) partners announce Pfizer's donation of the 500 millionth dose of Zithromax® (azithromycin) Tablets, an antibiotic used to treat trachoma in certain countries.
International study prompts rethink on the rise of diabetes in cities
- Details
- Category: Novo Nordisk
International research led by University College London (UCL) as part of the 'Cities Changing Diabetes' partnership programme challenges current scientific understanding of the rapid rise of diabetes in cities. The findings suggest that in cities around the world, social and cultural factors play a far more important role in the spread of the epidemic than previously thought.
Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim is launching a new research and development (R&D) strategy and a five-year R&D investment programme. This new plan was announced at its R&D press conference in Berlin. The company pledges to invest a total of 11 billion euros in its new R&D programme over the next five years. Of the total investment, 5 billion euros will go to preclinical R&D with 1.5 billion euro thereof planned for collaborations with external partners.
Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim today announced new collaborations with four major scientific partners to enrich research and development of novel therapeutic approaches for patients with inflammatory bowel disease (IBD), including the Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine.
Pfizer expands its patient assistance program
- Details
- Category: Pfizer
In response to the ongoing challenges patients face in paying their out-of-pocket costs for their prescription medicines, Pfizer announced that it will immediately double the allowable income level for its patient assistance program, so that even more patients in need could be eligible to receive their Pfizer medicines for free.
Merck recognized for digital workplace platform
- Details
- Category: Merck Group
The new EVA digital workplace at Merck, a leading science and technology company, was recently recognized with multiple Ragan Intranet Awards, an internationally renowned competition. The platform received prizes in the "Best Internal Social Networking" and "Best Design" categories.
More Pharma News ...
- AstraZeneca strengthens cardiovascular and metabolic disease portfolio with acquisition of ZS Pharma
- Johnson & Johnson announces agreement to acquire Novira Therapeutics, Inc.
- Sanofi and BioNTech announce cancer immunotherapy collaboration and license agreement
- Novo Nordisk and University of Washington to collaborate on exploring the role of the brain in regulating blood glucose and obesity
- Bristol-Myers Squibb to acquire Cardioxyl Pharmaceuticals, Inc.
- 'Science' says Abbott is a Top Employer
- Allergan plc confirms discussions regarding potential business combination transaction with Pfizer Inc.